S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:MRSN

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

$3.25
-0.09 (-2.69%)
(As of 04/19/2024 ET)
Today's Range
$3.18
$3.35
50-Day Range
$3.25
$5.94
52-Week Range
$0.80
$9.62
Volume
2.39 million shs
Average Volume
1.55 million shs
Market Capitalization
$394.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.29

Mersana Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
93.4% Upside
$6.29 Price Target
Short Interest
Bearish
8.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
1.04mentions of Mersana Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

161st out of 909 stocks

Pharmaceutical Preparations Industry

59th out of 427 stocks

MRSN stock logo

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN Stock Price History

MRSN Stock News Headlines

MRSN Mersana Therapeutics, Inc.
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
Mersana Therapeutics Inc MRSN
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
Q4 2023 Mersana Therapeutics Inc Earnings Call
Here's what Wall Street expects from Mersana Therapeutics's earnings
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.29
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+93.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-171,670,000.00
Net Margins
-465.80%
Pretax Margin
-465.80%

Debt

Sales & Book Value

Annual Sales
$36.85 million
Book Value
$0.31 per share

Miscellaneous

Free Float
106,140,000
Market Cap
$394.23 million
Optionable
Optionable
Beta
1.50
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Martin H. Huber M.D. (Age 63)
    President, CEO & Director
    Comp: $44k
  • Mr. Brian C. DeSchuytner (Age 45)
    Senior VP, CFO & COO
    Comp: $626.32k
  • Dr. Timothy B. Lowinger Ph.D. (Age 60)
    Senior VP and Chief Science & Technology Officer
    Comp: $666.3k
  • Ms. Alejandra Veronica Carvajal J.D. (Age 50)
    Senior VP, Secretary & Chief Legal Officer
    Comp: $606.51k
  • Mr. Mikhail Papisov Ph.D.
    Co-Founder
  • Mr. Ashish  MandeliaMr. Ashish Mandelia (Age 49)
    VP, Controller & Chief Accounting Officer
  • Mr. Jason Fredette
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Chuck Miller
    Senior Vice President of Regulatory Affairs
  • Mr. Marc Damelin
    Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
  • Dr. Tushar Misra Ph.D. (Age 63)
    Senior VP & Chief Manufacturing Officer
    Comp: $485.89k

MRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price target for 2024?

7 brokerages have issued 12 month target prices for Mersana Therapeutics' stock. Their MRSN share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.29 in the next twelve months. This suggests a possible upside of 93.4% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2024?

Mersana Therapeutics' stock was trading at $2.32 at the start of the year. Since then, MRSN stock has increased by 40.1% and is now trading at $3.25.
View the best growth stocks for 2024 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The firm earned $10.70 million during the quarter, compared to analyst estimates of $22.59 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 282.36% and a negative net margin of 465.80%. The company's revenue was down 27.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.44) EPS.

What ETF holds Mersana Therapeutics' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 288,017 shares of MRSN stock, representing 0.81% of its portfolio.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

Mersana Therapeutics (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRSN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners